Terns appoints former AstraZeneca CMO Ann Taylor to board

Terns Pharmaceuticals, Inc.

Ann E. Taylor, M.D. appointed as Class I director effective Sept 28, 2021.
Dr. Taylor brings >35 years of drug development experience, including CMO of AstraZeneca.
She will receive an initial option grant of 44,000 shares and $40k annual cash retainer.
Her expertise in NASH and clinical development supports Terns' pipeline.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ann E. Taylor

Director

TERN · Terns Pharmaceuticals, Inc.

Effective: 2021-09-28
Filed: September 29, 2021, 7:59 PM ET

On September 28, 2021, the Board of Directors (the “Board”) of Terns Pharmaceuticals, Inc. (the “Company”) appointed Ann E. Taylor, M.D. to serve as a Class I director until her successor is duly elected and qualified or until her earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ann E. Taylor was appointed as Director at Terns Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On September 28, 2021, the Board of Directors (the “Board”) of Terns Pharmaceuticals, Inc. (the “Company”) appointed Ann E. Taylor, M.D. to serve as a Class I director until her successor is duly elected and qualified or until her earlier death, resignation or removal.

View on SEC.gov

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-21-001914

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.